Patient support services
ServierONE offers patients helpful resources and tools for navigating treatment care, costs, and education throughout their journey.
Ordering and distribution network
National Drug Code (NDC)
10-digit code: 71334-100-01
11-digit code: 71334-0100-01
|250 mg/tablet||250-mg tablet: Blue oval-shaped film-coated tablet debossed “IVO” on one side and “250” on the other side|
|The red zero converts the 10-digit NDC to the 11-digit NDC. Some payers may require each NDC to be listed on the claim. Payer requirements regarding the use of NDCs may vary. Electronic data exchange generally requires use of the 11-digit NDC.|
How TIBSOVO is supplied: 250-mg tablets, supplied in 60-count bottles (30-day supply) with a desiccant canister
Storage: Store at 20 to 25 ºC (68 to 77 ºF)
Distribution network for TIBSOVO
TIBSOVO is only available through our specialty distributors and network specialty pharmacies.
McKesson Specialty Health
McKesson Plasma and Biologics
Cardinal Health (US)
Physician Office (Oncology)
Cardinal Health (Puerto Rico)
ASD Healthcare Customer Service
Biologics by McKesson
Optum Specialty Pharmacy
TIBSOVO resources for you and your practice
TIBSOVO Prescribing Information
TIBSOVO Product Guidea
TIBSOVO Differentiation Syndrome white paper
a This brochure contains reference to an older patient support services program. ServierONE is the new patient support services program for TIBSOVO. For more information, visit ServierONE.com.
Learn about a targeted approach to treating newly diagnosed and R/R AML with IDH1 mutations
Watch the interview with Dr. Gary Schiller,
Learn about a targeted approach to treating R/R AML with IDH1 mutations
Watch the interview with Dr. Muthu Veeraphuthiran, MD, MPH, FACP
Some participants in these videos are current or former employees of Agios or Servier.
Please see Full Prescribing Information, including BOXED WARNING.
Welcome to Target: AML—a podcast series from TIBSOVO
Target: AML is a podcast all about TIBSOVO and AML—from discussing the disease to uncovering the challenges and rewards of treating patients.
Episode 1: Jonathan Abbas, MD & Mark Levis, MD, PhD
On this episode of Target: AML, Jonathan Abbas, MD, and Mark Levis, MD, PhD, discuss the challenges and rewards of treating R/R mIDH1 AML.